Pharmaceutical kit

- Merck & Co., Inc.
Skip to: Description  ·  Claims  ·  References Cited  · Patent History  ·  Patent History
Description

FIG. 1 is an exploded perspective view, on a reduced scale, of a pharmaceutical kit showing our new design in the fully unfolded position with an uninserted insert card;

FIG. 2 is a full scale front plan view thereof;

FIG. 3 is a full scale end elevational view thereof;

FIG. 4 is a full scale rear plan view thereof;

FIG. 5 is a full scale right end elevational view thereof;

FIG. 6 is a full scale left end elevational view thereof;

FIG. 7 is a full scale front plan view of the insert card of the pharmaceutical kit shown in FIG. 1;

FIG. 8 is a full scale rear plan view of the insert card of the pharmaceutical kit shown in FIG. 1;

FIG. 9 is a full scale side elevational view of the insert card of the pharmaceutical kit shown in FIG. 1;

FIG. 10 is a full scale end elevational view of the insert card of the pharmaceutical kit shown in FIG. 1;

FIG. 11 is a full scale perspective view of the pharmaceutical kit shown in FIG. 1 in the fully folded position; and,

FIG. 12 is an exploded perspective view, on a reduced scale, in the fully unfolded position with a partially inserted insert card.

Claims

The ornamental design for a pharmaceutical kit, as shown and described.

Referenced Cited
U.S. Patent Documents
3504788 April 1970 Gray
3527190 September 1970 Huck
3677397 July 1972 Beckham
4199569 April 22, 1980 Chabala et al.
4243144 January 6, 1981 Margulies
4295567 October 20, 1981 Knudsen
4340141 July 20, 1982 Du Pont
4425339 January 10, 1984 Pitchford
4506789 March 26, 1985 Dlugosz
4534468 August 13, 1985 Nuckols et al.
4573580 March 4, 1986 Messer
4736849 April 12, 1988 Leonard et al.
4761406 August 2, 1988 Flora et al.
4848582 July 18, 1989 Levasseur et al.
4889237 December 26, 1989 Brandon
4889238 December 26, 1989 Batchelor
4974729 December 4, 1990 Steinnagel
5050739 September 24, 1991 Hannan et al
5242055 September 7, 1993 Pora
5265728 November 30, 1993 Allendorf et al.
5339960 August 23, 1994 Price
5393100 February 28, 1995 Coc
RE35445 February 11, 1997 Pora
5755462 May 26, 1998 Lupi
5833072 November 10, 1998 Lambelet, Jr.
5915559 June 29, 1999 Hulick et al.
5927500 July 27, 1999 Godfrey et al.
5994329 November 30, 1999 Daifotis et al.
6024222 February 15, 2000 Friberg et al.
Foreign Patent Documents
866616 March 1971 CA
0 511 726 November 1992 EP
2635507 February 1990 FR
1580583 December 1980 GB
2256853 December 1992 GB
WO 97/03896 February 1997 WO
WO 98/00351 January 1998 WO
WO 98/22072 May 1998 WO
WO 99/04773 February 1999 WO
WO 99/51214 October 1999 WO
Other references
  • Greenberg, Clin. Therap., vol. 6 (1984), “Overview of patient compliance with medication dosing: A literature Review”, pp. 592-599.
  • Schnitzer et al., Aging Clin. Exp. Res., vol. 12 (2000), pp. 1-12, “Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis”.
  • Adami et al., 6th Int'l Symposium on Clinical Disorders of Bone and Mineral Metabolism, Nov. 1999, “Rationale for once weekly dosing regimens with alendronate for the treatment and prevention of osteoporosis”, p. 48.
  • Bone III et al., 6th Int'l Symposium on Clinical Disorders of Bone and Mineral Metabolism, Nov. 1999,“Alendronate 70 mg once weekly is therapeutically equivalent to alendronate 10 mg daily”, p. 55.
  • Copy of dispenser package and insert for Heartgard 30® (ivermectin) chewables, Merck & Co., Inc., Oct. 1988.
Patent History
Patent number: D457246
Type: Grant
Filed: Dec 20, 1999
Date of Patent: May 14, 2002
Assignee: Merck & Co., Inc. (Rahway, NJ)
Inventors: Sidney Mazel (Basking Ridge, NJ), James M. Mundt (Warrington, PA)
Primary Examiner: Ian Simmons
Attorney, Agent or Law Firms: Anthony D. Sabatelli, Melvin Winokur
Application Number: 29/115,771
Classifications
Current U.S. Class: Interrelated Indication Or Reaction Set (i.e., "test Kit") (64) (D24/223)
International Classification: 2402;